Dare Bioscience (DARE) announced that all rights to Ovaprene, the company’s first-in-category, investigational, hormone-free monthly intravaginal contraceptive, will be returned to Dare by Bayer HealthCare (BAYRY) as a result of Bayer electing to terminate the license agreement between the parties as part of a strategic prioritization. In accordance with the license agreement, the termination will be effective in February 2026. With the Phase 3 program advancing with non-dilutive grant support, the return of rights will provide Dare with full control of a late-stage asset that is differentiated in a large market with significant unmet need.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Dare Bioscience receives $3.6M in additional grant funding
- Daré Bioscience’s Promising Growth and Product Launches Justify Buy Rating
- Daré Bioscience’s Earnings Call Highlights Growth and Challenges
- Daré Bioscience Advances Women’s Health Innovations
- Dare Bioscience reports Q3 EPS (28c), consensus (38c)